Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,2775616,Cmax,"4. Following a fatty meal, Cmax for Hf was increased from 184 +/- 115 micrograms l-1 (fasting) to 1218 +/- 464 micrograms l-1 (fed).",Pharmacokinetics of halofantrine in man: effects of food and dose size. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775616/),[μg] / [l],184,6621,DB01218,Halofantrine
,2775616,Cmax,"4. Following a fatty meal, Cmax for Hf was increased from 184 +/- 115 micrograms l-1 (fasting) to 1218 +/- 464 micrograms l-1 (fed).",Pharmacokinetics of halofantrine in man: effects of food and dose size. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775616/),[μg] / [l],1218,6622,DB01218,Halofantrine
,2775616,AUC,AUC for Hf was increased from 3.9 +/- 2.6 mg l-1 h (fasting) to 11.3 +/- 3.5 mg l-1 h following a fatty meal.,Pharmacokinetics of halofantrine in man: effects of food and dose size. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775616/),[h·mg] / [l],3.9,6623,DB01218,Halofantrine
,2775616,AUC,AUC for Hf was increased from 3.9 +/- 2.6 mg l-1 h (fasting) to 11.3 +/- 3.5 mg l-1 h following a fatty meal.,Pharmacokinetics of halofantrine in man: effects of food and dose size. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775616/),[h·mg] / [l],11.3,6624,DB01218,Halofantrine
,8866337,volume of distribution (Vd),"Halofantrine parameter estimates (mean +/- s.d.) were: volume of distribution (Vd), 7.53 +/- 1.45 mL (g liver)-1; clearance (CL), 0.11 +/- 0.07 mL min-1 (g liver)-1; initial distribution half-life (initial t1/2), 14.62 +/- 2.38 min; terminal half-life (terminal t1/2), 138.7 +/- 178.8 min; AUC 606 +/- 194 mg mL-1 min-1 (g liver)-1; elimination rate constant (Ke), 0.0135 +/- 0.012 min-1.",Mefloquine effect on disposition of halofantrine in the isolated perfused rat liver. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866337/),ml,7.53,8764,DB01218,Halofantrine
,8866337,clearance (CL),"Halofantrine parameter estimates (mean +/- s.d.) were: volume of distribution (Vd), 7.53 +/- 1.45 mL (g liver)-1; clearance (CL), 0.11 +/- 0.07 mL min-1 (g liver)-1; initial distribution half-life (initial t1/2), 14.62 +/- 2.38 min; terminal half-life (terminal t1/2), 138.7 +/- 178.8 min; AUC 606 +/- 194 mg mL-1 min-1 (g liver)-1; elimination rate constant (Ke), 0.0135 +/- 0.012 min-1.",Mefloquine effect on disposition of halofantrine in the isolated perfused rat liver. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866337/),[ml] / [min],0.11,8765,DB01218,Halofantrine
,8866337,initial distribution half-life (initial t1/2),"Halofantrine parameter estimates (mean +/- s.d.) were: volume of distribution (Vd), 7.53 +/- 1.45 mL (g liver)-1; clearance (CL), 0.11 +/- 0.07 mL min-1 (g liver)-1; initial distribution half-life (initial t1/2), 14.62 +/- 2.38 min; terminal half-life (terminal t1/2), 138.7 +/- 178.8 min; AUC 606 +/- 194 mg mL-1 min-1 (g liver)-1; elimination rate constant (Ke), 0.0135 +/- 0.012 min-1.",Mefloquine effect on disposition of halofantrine in the isolated perfused rat liver. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866337/),min,14.62,8766,DB01218,Halofantrine
,8866337,terminal half-life (terminal t1/2),"Halofantrine parameter estimates (mean +/- s.d.) were: volume of distribution (Vd), 7.53 +/- 1.45 mL (g liver)-1; clearance (CL), 0.11 +/- 0.07 mL min-1 (g liver)-1; initial distribution half-life (initial t1/2), 14.62 +/- 2.38 min; terminal half-life (terminal t1/2), 138.7 +/- 178.8 min; AUC 606 +/- 194 mg mL-1 min-1 (g liver)-1; elimination rate constant (Ke), 0.0135 +/- 0.012 min-1.",Mefloquine effect on disposition of halofantrine in the isolated perfused rat liver. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866337/),min,138.7,8767,DB01218,Halofantrine
,8866337,AUC,"Halofantrine parameter estimates (mean +/- s.d.) were: volume of distribution (Vd), 7.53 +/- 1.45 mL (g liver)-1; clearance (CL), 0.11 +/- 0.07 mL min-1 (g liver)-1; initial distribution half-life (initial t1/2), 14.62 +/- 2.38 min; terminal half-life (terminal t1/2), 138.7 +/- 178.8 min; AUC 606 +/- 194 mg mL-1 min-1 (g liver)-1; elimination rate constant (Ke), 0.0135 +/- 0.012 min-1.",Mefloquine effect on disposition of halofantrine in the isolated perfused rat liver. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866337/),[mg] / [min·ml],606,8768,DB01218,Halofantrine
,8866337,elimination rate constant (Ke),"Halofantrine parameter estimates (mean +/- s.d.) were: volume of distribution (Vd), 7.53 +/- 1.45 mL (g liver)-1; clearance (CL), 0.11 +/- 0.07 mL min-1 (g liver)-1; initial distribution half-life (initial t1/2), 14.62 +/- 2.38 min; terminal half-life (terminal t1/2), 138.7 +/- 178.8 min; AUC 606 +/- 194 mg mL-1 min-1 (g liver)-1; elimination rate constant (Ke), 0.0135 +/- 0.012 min-1.",Mefloquine effect on disposition of halofantrine in the isolated perfused rat liver. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866337/),1/[min],0.0135,8769,DB01218,Halofantrine
<,8742945,solubility,"At premicellar (fasted) concentrations of NaTC (< 5 mM), the solubility and intrinsic dissolution rate were very low (< 15 micrograms/mL; < 0.01 microgram s-1 cm-2).",A physicochemical basis for the effect of food on the absolute oral bioavailability of halofantrine. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8742945/),[μg] / [ml],15,15727,DB01218,Halofantrine
<,8742945,intrinsic dissolution rate,"At premicellar (fasted) concentrations of NaTC (< 5 mM), the solubility and intrinsic dissolution rate were very low (< 15 micrograms/mL; < 0.01 microgram s-1 cm-2).",A physicochemical basis for the effect of food on the absolute oral bioavailability of halofantrine. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8742945/),[μg] / [ml],15,15728,DB01218,Halofantrine
<,8742945,intrinsic dissolution rate,"At premicellar (fasted) concentrations of NaTC (< 5 mM), the solubility and intrinsic dissolution rate were very low (< 15 micrograms/mL; < 0.01 microgram s-1 cm-2).",A physicochemical basis for the effect of food on the absolute oral bioavailability of halofantrine. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8742945/),[μg] / [(cm)^2·s],0.01,15729,DB01218,Halofantrine
,9885302,adsorption capacities,"Other antacids investigated were magnesium trisilicate and aluminium hydroxide and these had Hf-adsorption capacities of 23 and 43%, respectively.","Altered pharmacokinetics of halofantrine by an antacid, magnesium carbonate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9885302/),%,23,21403,DB01218,Halofantrine
,9885302,adsorption capacities,"Other antacids investigated were magnesium trisilicate and aluminium hydroxide and these had Hf-adsorption capacities of 23 and 43%, respectively.","Altered pharmacokinetics of halofantrine by an antacid, magnesium carbonate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9885302/),%,43,21404,DB01218,Halofantrine
,17417075,Cmax,"For example, the parameter values for HF alone and with AQ were: Cmax 144 +/- 53 versus 164 +/- 58 microg/L; T1/2beta 142 +/- 23 versus 139 +/- 28 hours; Cl/F 37.3 +/- 13.9 versus 32.3 +/- 11.4 L/h; and metabolic ratio 1.2 +/- 0.5 vs 1.1 +/- 0.6 Similarly, the disposition of HFM was not significantly altered (P > 0.05) after an earlier exposure to amodiaquine.",Effects of prior administration of amodiaquine on the disposition of halofantrine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17417075/),[μg] / [l],144,34074,DB01218,Halofantrine
,17417075,Cmax,"For example, the parameter values for HF alone and with AQ were: Cmax 144 +/- 53 versus 164 +/- 58 microg/L; T1/2beta 142 +/- 23 versus 139 +/- 28 hours; Cl/F 37.3 +/- 13.9 versus 32.3 +/- 11.4 L/h; and metabolic ratio 1.2 +/- 0.5 vs 1.1 +/- 0.6 Similarly, the disposition of HFM was not significantly altered (P > 0.05) after an earlier exposure to amodiaquine.",Effects of prior administration of amodiaquine on the disposition of halofantrine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17417075/),[μg] / [l],164,34075,DB01218,Halofantrine
,17417075,T1/2beta,"For example, the parameter values for HF alone and with AQ were: Cmax 144 +/- 53 versus 164 +/- 58 microg/L; T1/2beta 142 +/- 23 versus 139 +/- 28 hours; Cl/F 37.3 +/- 13.9 versus 32.3 +/- 11.4 L/h; and metabolic ratio 1.2 +/- 0.5 vs 1.1 +/- 0.6 Similarly, the disposition of HFM was not significantly altered (P > 0.05) after an earlier exposure to amodiaquine.",Effects of prior administration of amodiaquine on the disposition of halofantrine in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17417075/),h,142,34076,DB01218,Halofantrine
,17417075,T1/2beta,"For example, the parameter values for HF alone and with AQ were: Cmax 144 +/- 53 versus 164 +/- 58 microg/L; T1/2beta 142 +/- 23 versus 139 +/- 28 hours; Cl/F 37.3 +/- 13.9 versus 32.3 +/- 11.4 L/h; and metabolic ratio 1.2 +/- 0.5 vs 1.1 +/- 0.6 Similarly, the disposition of HFM was not significantly altered (P > 0.05) after an earlier exposure to amodiaquine.",Effects of prior administration of amodiaquine on the disposition of halofantrine in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17417075/),h,139,34077,DB01218,Halofantrine
,17417075,Cl/F,"For example, the parameter values for HF alone and with AQ were: Cmax 144 +/- 53 versus 164 +/- 58 microg/L; T1/2beta 142 +/- 23 versus 139 +/- 28 hours; Cl/F 37.3 +/- 13.9 versus 32.3 +/- 11.4 L/h; and metabolic ratio 1.2 +/- 0.5 vs 1.1 +/- 0.6 Similarly, the disposition of HFM was not significantly altered (P > 0.05) after an earlier exposure to amodiaquine.",Effects of prior administration of amodiaquine on the disposition of halofantrine in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17417075/),[l] / [h],37.3,34078,DB01218,Halofantrine
,17417075,Cl/F,"For example, the parameter values for HF alone and with AQ were: Cmax 144 +/- 53 versus 164 +/- 58 microg/L; T1/2beta 142 +/- 23 versus 139 +/- 28 hours; Cl/F 37.3 +/- 13.9 versus 32.3 +/- 11.4 L/h; and metabolic ratio 1.2 +/- 0.5 vs 1.1 +/- 0.6 Similarly, the disposition of HFM was not significantly altered (P > 0.05) after an earlier exposure to amodiaquine.",Effects of prior administration of amodiaquine on the disposition of halofantrine in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17417075/),[l] / [h],32.3,34079,DB01218,Halofantrine
,17417075,metabolic ratio,"For example, the parameter values for HF alone and with AQ were: Cmax 144 +/- 53 versus 164 +/- 58 microg/L; T1/2beta 142 +/- 23 versus 139 +/- 28 hours; Cl/F 37.3 +/- 13.9 versus 32.3 +/- 11.4 L/h; and metabolic ratio 1.2 +/- 0.5 vs 1.1 +/- 0.6 Similarly, the disposition of HFM was not significantly altered (P > 0.05) after an earlier exposure to amodiaquine.",Effects of prior administration of amodiaquine on the disposition of halofantrine in healthy volunteers. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17417075/),,1.2,34080,DB01218,Halofantrine
,17417075,metabolic ratio,"For example, the parameter values for HF alone and with AQ were: Cmax 144 +/- 53 versus 164 +/- 58 microg/L; T1/2beta 142 +/- 23 versus 139 +/- 28 hours; Cl/F 37.3 +/- 13.9 versus 32.3 +/- 11.4 L/h; and metabolic ratio 1.2 +/- 0.5 vs 1.1 +/- 0.6 Similarly, the disposition of HFM was not significantly altered (P > 0.05) after an earlier exposure to amodiaquine.",Effects of prior administration of amodiaquine on the disposition of halofantrine in healthy volunteers. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17417075/),,1.1,34081,DB01218,Halofantrine
,11298069,accumulation half-times,Mean accumulation half-times (days) for halofantrine were: 7.0 +/- 4.8 [(+)-halofantrine] and 7.3 +/- 4.8 [(-)-halofantrine].,Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11298069/),d,7.0,41375,DB01218,Halofantrine
,11298069,accumulation half-times,Mean accumulation half-times (days) for halofantrine were: 7.0 +/- 4.8 [(+)-halofantrine] and 7.3 +/- 4.8 [(-)-halofantrine].,Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11298069/),d,7.3,41376,DB01218,Halofantrine
,11298069,steady-state concentrations,Mean steady-state concentrations were: 97.6 +/- 52.0 ng ml(-1) [(+)-halofantrine] and 48.5 +/- 20.8 [(-)-halofantrine].,Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11298069/),[ng] / [ml],97.6,41377,DB01218,Halofantrine
,11298069,steady-state concentrations,Mean steady-state concentrations were: 97.6 +/- 52.0 ng ml(-1) [(+)-halofantrine] and 48.5 +/- 20.8 [(-)-halofantrine].,Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11298069/),,48.5,41378,DB01218,Halofantrine
,11298069,Steady-state oral clearance,Steady-state oral clearance was: 139 +/- 73 l h(-1) [(+)-halofantrine] and 265 +/- 135 l h(-1) [(-)-halofantrine].,Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11298069/),[l] / [h],139,41379,DB01218,Halofantrine
,11298069,Steady-state oral clearance,Steady-state oral clearance was: 139 +/- 73 l h(-1) [(+)-halofantrine] and 265 +/- 135 l h(-1) [(-)-halofantrine].,Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11298069/),[l] / [h],265,41380,DB01218,Halofantrine
greater,9687337,absolute bioavailability,"Although food enhances the absorption of Hf, it also alters the intrinsic pharmacokinetics of Hf as the observed postprandial absolute bioavailability was greater than 100% (Humberstone et al., J. Pharm. Sci. 1996, 85, 525-529).",Association of halofantrine with postprandially derived plasma lipoproteins decreases its clearance relative to administration in the fasted state. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687337/),%,100,45361,DB01218,Halofantrine
,11891669,AUC (+):(-) ratio,Stereoselectivity was more pronounced for HF (AUC (+):(-) ratio= 1.58) than DHF (AUC (+):(-) ratio =1.16) in heart tissue.,Stereoselective halofantrine and desbutylhalofantrine disposition in the rat: cardiac and plasma concentrations and plasma protein binding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11891669/),,1.58,57177,DB01218,Halofantrine
,11891669,AUC (+):(-) ratio,Stereoselectivity was more pronounced for HF (AUC (+):(-) ratio= 1.58) than DHF (AUC (+):(-) ratio =1.16) in heart tissue.,Stereoselective halofantrine and desbutylhalofantrine disposition in the rat: cardiac and plasma concentrations and plasma protein binding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11891669/),,1.16,57178,DB01218,Halofantrine
,11891669,Heart:plasma AUC ratios,"Heart:plasma AUC ratios of 6.8-8.0, and 9.3-21, were observed for HF and DHF enantiomers, respectively, indicating that DHF has greater cardiac uptake than HF itself.",Stereoselective halofantrine and desbutylhalofantrine disposition in the rat: cardiac and plasma concentrations and plasma protein binding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11891669/),,6.8-8.0,57179,DB01218,Halofantrine
,11891669,Heart:plasma AUC ratios,"Heart:plasma AUC ratios of 6.8-8.0, and 9.3-21, were observed for HF and DHF enantiomers, respectively, indicating that DHF has greater cardiac uptake than HF itself.",Stereoselective halofantrine and desbutylhalofantrine disposition in the rat: cardiac and plasma concentrations and plasma protein binding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11891669/),,9.3-21,57180,DB01218,Halofantrine
,12426515,Maximum QTc interval prolongation,Maximum QTc interval prolongation increased from 17 +/- 6 ms when halofantrine was administered with water to 31 +/- 12 ms when it was administered with grapefruit juice (P <.0005).,Pharmacokinetic and pharmacodynamic interaction between grapefruit juice and halofantrine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12426515/),ms,17,76266,DB01218,Halofantrine
,12426515,Maximum QTc interval prolongation,Maximum QTc interval prolongation increased from 17 +/- 6 ms when halofantrine was administered with water to 31 +/- 12 ms when it was administered with grapefruit juice (P <.0005).,Pharmacokinetic and pharmacodynamic interaction between grapefruit juice and halofantrine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12426515/),m,31,76267,DB01218,Halofantrine
,17089336,ratio of intrinsic formation clearances,Formation of (-)-DHF exceeded that of (+)-DHF in liver microsomes [(-):(+) ratio of intrinsic formation clearances = 1.4].,The stereoselective metabolism of halofantrine to desbutylhalofantrine in the rat: evidence of tissue-specific enantioselectivity in microsomal metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17089336/),,1.4,77047,DB01218,Halofantrine
,8915121,fever-clearance time,"The 95 evaluable patients were all successfully treated, with a mean fever-clearance time of 22.5 h (range 4-76 h) and a mean parasite-clearance time of 35.6 h (range 15-66 h).","Evaluation of the safety and efficacy of micronized halofantrine in the treatment of semi-immune patients with acute, Plasmodium falciparum malaria. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8915121/),h,22.5,97077,DB01218,Halofantrine
,8915121,parasite-clearance time,"The 95 evaluable patients were all successfully treated, with a mean fever-clearance time of 22.5 h (range 4-76 h) and a mean parasite-clearance time of 35.6 h (range 15-66 h).","Evaluation of the safety and efficacy of micronized halofantrine in the treatment of semi-immune patients with acute, Plasmodium falciparum malaria. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8915121/),h,35.6,97078,DB01218,Halofantrine
,7995326,AUC(0)84h,AUC(0)84h values were higher for (+)halofantrine (9917 micrograms.ml-1.h) than for (-)-halofantrine (6127 micrograms.ml-1.h).,Plasma concentrations of the enantiomers of halofantrine and its main metabolite in malaria patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7995326/),[h·μg] / [ml],9917,106108,DB01218,Halofantrine
,7995326,AUC(0)84h,AUC(0)84h values were higher for (+)halofantrine (9917 micrograms.ml-1.h) than for (-)-halofantrine (6127 micrograms.ml-1.h).,Plasma concentrations of the enantiomers of halofantrine and its main metabolite in malaria patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7995326/),[h·μg] / [ml],6127,106109,DB01218,Halofantrine
,11523065,ratios of AUC(0-infinity),"After (+/-)-DHF, the mean (+):(-) ratios of AUC(0-infinity) after oral and intravenous dosing were 3.7 and 2.8, respectively.","Stereoselective pharmacokinetics of desbutylhalofantrine, a metabolite of halofantrine, in the rat after administration of the racemic metabolite or parent drug. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11523065/),,3.7,108080,DB01218,Halofantrine
,11523065,ratios of AUC(0-infinity),"After (+/-)-DHF, the mean (+):(-) ratios of AUC(0-infinity) after oral and intravenous dosing were 3.7 and 2.8, respectively.","Stereoselective pharmacokinetics of desbutylhalofantrine, a metabolite of halofantrine, in the rat after administration of the racemic metabolite or parent drug. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11523065/),,2.8,108081,DB01218,Halofantrine
,11523065,t(1/2),There were no significant differences between the enantiomers in t(1/2) (mean 14-23 h) or t(max) (mean 10-12 h) after intravenous or oral administration of DHF.,"Stereoselective pharmacokinetics of desbutylhalofantrine, a metabolite of halofantrine, in the rat after administration of the racemic metabolite or parent drug. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11523065/),h,14-23,108082,DB01218,Halofantrine
,11523065,t(max),There were no significant differences between the enantiomers in t(1/2) (mean 14-23 h) or t(max) (mean 10-12 h) after intravenous or oral administration of DHF.,"Stereoselective pharmacokinetics of desbutylhalofantrine, a metabolite of halofantrine, in the rat after administration of the racemic metabolite or parent drug. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11523065/),h,10-12,108083,DB01218,Halofantrine
>,11523065,Oral bioavailability,Oral bioavailability estimates of DHF enantiomers (>59%) were higher than those previously estimated for HF in the rat.,"Stereoselective pharmacokinetics of desbutylhalofantrine, a metabolite of halofantrine, in the rat after administration of the racemic metabolite or parent drug. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11523065/),%,59,108084,DB01218,Halofantrine
,21256961,AUC,"However, in vivo bioavailability studies in rats showed the same plasma concentration-time profiles when dosing 10mg/kg halofantrine at two dose levels of F6H8, MCT or F6H8:MCT (1:1) (AUC ranged from 3058 to 3447hng/ml, T(max)∼6.0h, C(max) ranged from 168 to 265mg/ml).","A novel excipient, 1-perfluorohexyloctane shows limited utility for the oral delivery of poorly water-soluble drugs. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21256961/),[hng] / [ml],3058 to 3447,110524,DB01218,Halofantrine
,21256961,T(max),"However, in vivo bioavailability studies in rats showed the same plasma concentration-time profiles when dosing 10mg/kg halofantrine at two dose levels of F6H8, MCT or F6H8:MCT (1:1) (AUC ranged from 3058 to 3447hng/ml, T(max)∼6.0h, C(max) ranged from 168 to 265mg/ml).","A novel excipient, 1-perfluorohexyloctane shows limited utility for the oral delivery of poorly water-soluble drugs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21256961/),h,∼6,110525,DB01218,Halofantrine
,21256961,T(max),"However, in vivo bioavailability studies in rats showed the same plasma concentration-time profiles when dosing 10mg/kg halofantrine at two dose levels of F6H8, MCT or F6H8:MCT (1:1) (AUC ranged from 3058 to 3447hng/ml, T(max)∼6.0h, C(max) ranged from 168 to 265mg/ml).","A novel excipient, 1-perfluorohexyloctane shows limited utility for the oral delivery of poorly water-soluble drugs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21256961/),h,.0,110526,DB01218,Halofantrine
,21256961,C(max),"However, in vivo bioavailability studies in rats showed the same plasma concentration-time profiles when dosing 10mg/kg halofantrine at two dose levels of F6H8, MCT or F6H8:MCT (1:1) (AUC ranged from 3058 to 3447hng/ml, T(max)∼6.0h, C(max) ranged from 168 to 265mg/ml).","A novel excipient, 1-perfluorohexyloctane shows limited utility for the oral delivery of poorly water-soluble drugs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21256961/),[mg] / [ml],168 to 265,110527,DB01218,Halofantrine
,21256961,T(max),"Generally, the addition of polysorbate 80 shortened the time to reach C(max) (T(max) ranged 1.3-4.5h), but had limited effect on the bioavailability from F6H8 or MCT in combination with polysorbate 80 (4:1) (AUC ranged from 3807 to 4403 (hng/ml)).","A novel excipient, 1-perfluorohexyloctane shows limited utility for the oral delivery of poorly water-soluble drugs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21256961/),h,1.3-4.5,110528,DB01218,Halofantrine
,21256961,AUC,"Generally, the addition of polysorbate 80 shortened the time to reach C(max) (T(max) ranged 1.3-4.5h), but had limited effect on the bioavailability from F6H8 or MCT in combination with polysorbate 80 (4:1) (AUC ranged from 3807 to 4403 (hng/ml)).","A novel excipient, 1-perfluorohexyloctane shows limited utility for the oral delivery of poorly water-soluble drugs. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21256961/),[hng] / [ml],3807 to 4403,110529,DB01218,Halofantrine
,21256961,AUC,"Although a synergistic effect was obtained with halofantrine in F6H8:MCT:polysorbate 80 (2:2:1) (AUC 5574±675hng/ml; mean±SEM), it was not superior to dosing halofantrine in pure polysorbarte 80 (AUC 7370±579hng/ml; mean±SEM).","A novel excipient, 1-perfluorohexyloctane shows limited utility for the oral delivery of poorly water-soluble drugs. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21256961/),[hng] / [ml],5574,110530,DB01218,Halofantrine
,21256961,AUC,"Although a synergistic effect was obtained with halofantrine in F6H8:MCT:polysorbate 80 (2:2:1) (AUC 5574±675hng/ml; mean±SEM), it was not superior to dosing halofantrine in pure polysorbarte 80 (AUC 7370±579hng/ml; mean±SEM).","A novel excipient, 1-perfluorohexyloctane shows limited utility for the oral delivery of poorly water-soluble drugs. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21256961/),[hng] / [ml],7370,110531,DB01218,Halofantrine
,7955774,half-life of absorption,The mean half-life of absorption is 4 hours and Cmax is significantly lower than that obtained in healthy individuals.,Clinical pharmacokinetics of halofantrine. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955774/),h,4,116437,DB01218,Halofantrine
,7955774,terminal elimination half-life,The terminal elimination half-life is 5 days in patients with malaria.,Clinical pharmacokinetics of halofantrine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955774/),d,5,116438,DB01218,Halofantrine
,12959277,parasite clearance time,"Halofantrine cleared parasitaemia rapidly in all but one patient, with a mean (s.d.) parasite clearance time of 71 (29) h.","Pharmacokinetics, efficacy and toxicity of parenteral halofantrine in uncomplicated malaria. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959277/),h,71,129134,DB01218,Halofantrine
,12959277,V1,3 An open two-compartment model with the following parameters described the pharmacokinetics of halofantrine in acute malaria (mean (s.d)): V1 = 0.36 (0.18) l kg(-1); CL = 0.355 (0.18) l h(-1) kg(-1); t1/2alpha = 0.19 (0.12) h; t1/2beta = 14.4 (7.5) h.,"Pharmacokinetics, efficacy and toxicity of parenteral halofantrine in uncomplicated malaria. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959277/),[l] / [kg],0.36,129135,DB01218,Halofantrine
,12959277,CL,3 An open two-compartment model with the following parameters described the pharmacokinetics of halofantrine in acute malaria (mean (s.d)): V1 = 0.36 (0.18) l kg(-1); CL = 0.355 (0.18) l h(-1) kg(-1); t1/2alpha = 0.19 (0.12) h; t1/2beta = 14.4 (7.5) h.,"Pharmacokinetics, efficacy and toxicity of parenteral halofantrine in uncomplicated malaria. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959277/),[l] / [h·kg],0.355,129136,DB01218,Halofantrine
,12959277,t1/2alpha,3 An open two-compartment model with the following parameters described the pharmacokinetics of halofantrine in acute malaria (mean (s.d)): V1 = 0.36 (0.18) l kg(-1); CL = 0.355 (0.18) l h(-1) kg(-1); t1/2alpha = 0.19 (0.12) h; t1/2beta = 14.4 (7.5) h.,"Pharmacokinetics, efficacy and toxicity of parenteral halofantrine in uncomplicated malaria. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959277/),h,0.19,129137,DB01218,Halofantrine
,12959277,t1/2beta,3 An open two-compartment model with the following parameters described the pharmacokinetics of halofantrine in acute malaria (mean (s.d)): V1 = 0.36 (0.18) l kg(-1); CL = 0.355 (0.18) l h(-1) kg(-1); t1/2alpha = 0.19 (0.12) h; t1/2beta = 14.4 (7.5) h.,"Pharmacokinetics, efficacy and toxicity of parenteral halofantrine in uncomplicated malaria. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959277/),h,14.4,129138,DB01218,Halofantrine
,8116811,parasite clearance time,"There were no significant differences in efficacy between halofantrine and Q7T7 (P > 0.1) as assessed by cure rate (92% versus 85%), mean parasite clearance time (82 hr versus 81 hr), or mean fever clearance time (93 hr versus 99 hr).",Efficacy and tolerance of extended-dose halofantrine for drug-resistant falciparum malaria in Thailand. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8116811/),h,82,134636,DB01218,Halofantrine
,8116811,parasite clearance time,"There were no significant differences in efficacy between halofantrine and Q7T7 (P > 0.1) as assessed by cure rate (92% versus 85%), mean parasite clearance time (82 hr versus 81 hr), or mean fever clearance time (93 hr versus 99 hr).",Efficacy and tolerance of extended-dose halofantrine for drug-resistant falciparum malaria in Thailand. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8116811/),h,81,134637,DB01218,Halofantrine
,8116811,fever clearance time,"There were no significant differences in efficacy between halofantrine and Q7T7 (P > 0.1) as assessed by cure rate (92% versus 85%), mean parasite clearance time (82 hr versus 81 hr), or mean fever clearance time (93 hr versus 99 hr).",Efficacy and tolerance of extended-dose halofantrine for drug-resistant falciparum malaria in Thailand. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8116811/),h,93,134638,DB01218,Halofantrine
,8116811,fever clearance time,"There were no significant differences in efficacy between halofantrine and Q7T7 (P > 0.1) as assessed by cure rate (92% versus 85%), mean parasite clearance time (82 hr versus 81 hr), or mean fever clearance time (93 hr versus 99 hr).",Efficacy and tolerance of extended-dose halofantrine for drug-resistant falciparum malaria in Thailand. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8116811/),h,99,134639,DB01218,Halofantrine
,8116811,side effects,"The side effects score was lower (2 versus 11; P < 0.001), there were less days on which side effects occurred (2.0 days versus 5.5 days; P < 0.001), and fewer patients had adverse effects on every treatment day (4% versus 42%; P < 0.01).",Efficacy and tolerance of extended-dose halofantrine for drug-resistant falciparum malaria in Thailand. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8116811/),,2,134640,DB01218,Halofantrine
,3893840,half-lives (t1/2 beta),"In healthy subjects, the cinchona alkaloids (quinine and quinidine), primaquine and proguanil (chloroguanide) are all rapidly eliminated with half-lives (t1/2 beta) of between 6 and 12 hours.",Clinical pharmacokinetics of antimalarial drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3893840/),h,6 and 12,134980,DB01218,Halofantrine
,3893840,t1/2 beta,Chloroquine (t1/2 beta 6 to 50 days) and mefloquine (t1/2 beta 6.5 to 33 days) have extensive tissue distribution and prolonged activity after a single dose.,Clinical pharmacokinetics of antimalarial drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3893840/),d,6 to 50,134981,DB01218,Halofantrine
,3893840,t1/2 beta,Chloroquine (t1/2 beta 6 to 50 days) and mefloquine (t1/2 beta 6.5 to 33 days) have extensive tissue distribution and prolonged activity after a single dose.,Clinical pharmacokinetics of antimalarial drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3893840/),d,6.5 to 33,134982,DB01218,Halofantrine
,3893840,t1/2,"Pyrimethamine (t1/2 35 to 175 hours) has more limited tissue distribution, plasma and erythrocyte concentrations are similar, and 85% of the drug in plasma is bound to plasma proteins.",Clinical pharmacokinetics of antimalarial drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3893840/),h,35 to 175,134983,DB01218,Halofantrine
,10750517,parasite clearance time (PCT),The parasite clearance time (PCT) of these drugs ranged between two days and a week and the fever clearance time (FCT) was within 48 hours.,Comparative efficacy and safety of chloroquine and alternative antimalarial drugs: a meta-analysis from six African countries. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10750517/),d,two,138310,DB01218,Halofantrine
,10750517,fever clearance time (FCT),The parasite clearance time (PCT) of these drugs ranged between two days and a week and the fever clearance time (FCT) was within 48 hours.,Comparative efficacy and safety of chloroquine and alternative antimalarial drugs: a meta-analysis from six African countries. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10750517/),h,48,138311,DB01218,Halofantrine
,7768075,elimination half-life,Halofantrine elimination half-life was significantly shorter in patients with malaria than healthy control subjects (9.5 versus 15.8 days).,Pharmacokinetics of an extended-dose halofantrine regimen in patients with malaria and in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768075/),d,9.5,139724,DB01218,Halofantrine
,7768075,elimination half-life,Halofantrine elimination half-life was significantly shorter in patients with malaria than healthy control subjects (9.5 versus 15.8 days).,Pharmacokinetics of an extended-dose halofantrine regimen in patients with malaria and in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768075/),d,15.8,139725,DB01218,Halofantrine
,23058047,apparent clearance (CL),"The population estimates of apparent clearance (CL), volume of compartment one (V1), distributional clearance (CLD) and volume of compartment two (V2) of HF in healthy volunteers were 2453 l/day (102 l/h), 2386 l, 716 l/day (29.8 l/h) and 2641 l, respectively.",Population pharmacokinetics of halofantrine in healthy volunteers and patients with symptomatic falciparum malaria. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23058047/),[l] / [d],2453,148464,DB01218,Halofantrine
,23058047,volume of compartment one (V1),"The population estimates of apparent clearance (CL), volume of compartment one (V1), distributional clearance (CLD) and volume of compartment two (V2) of HF in healthy volunteers were 2453 l/day (102 l/h), 2386 l, 716 l/day (29.8 l/h) and 2641 l, respectively.",Population pharmacokinetics of halofantrine in healthy volunteers and patients with symptomatic falciparum malaria. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23058047/),l,2386,148465,DB01218,Halofantrine
,23058047,volume of compartment one (V1),"The population estimates of apparent clearance (CL), volume of compartment one (V1), distributional clearance (CLD) and volume of compartment two (V2) of HF in healthy volunteers were 2453 l/day (102 l/h), 2386 l, 716 l/day (29.8 l/h) and 2641 l, respectively.",Population pharmacokinetics of halofantrine in healthy volunteers and patients with symptomatic falciparum malaria. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23058047/),[l] / [d],716,148466,DB01218,Halofantrine
,23058047,distributional clearance (CLD),"The population estimates of apparent clearance (CL), volume of compartment one (V1), distributional clearance (CLD) and volume of compartment two (V2) of HF in healthy volunteers were 2453 l/day (102 l/h), 2386 l, 716 l/day (29.8 l/h) and 2641 l, respectively.",Population pharmacokinetics of halofantrine in healthy volunteers and patients with symptomatic falciparum malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23058047/),l,2386,148467,DB01218,Halofantrine
,23058047,distributional clearance (CLD),"The population estimates of apparent clearance (CL), volume of compartment one (V1), distributional clearance (CLD) and volume of compartment two (V2) of HF in healthy volunteers were 2453 l/day (102 l/h), 2386 l, 716 l/day (29.8 l/h) and 2641 l, respectively.",Population pharmacokinetics of halofantrine in healthy volunteers and patients with symptomatic falciparum malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23058047/),[l] / [d],716,148468,DB01218,Halofantrine
,23058047,volume of compartment two (V2),"The population estimates of apparent clearance (CL), volume of compartment one (V1), distributional clearance (CLD) and volume of compartment two (V2) of HF in healthy volunteers were 2453 l/day (102 l/h), 2386 l, 716 l/day (29.8 l/h) and 2641 l, respectively.",Population pharmacokinetics of halofantrine in healthy volunteers and patients with symptomatic falciparum malaria. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23058047/),l,2641,148469,DB01218,Halofantrine
,26486790,C max,"In the in vivo studies, the super-SNEDDS concept proved valid in a rat model with a significantly larger C max for the super-SNEDDS (964 ± 167 ng/mL) than for the SNEDDS (506 ± 112 ng/mL).",The Effect of Digestion and Drug Load on Halofantrine Absorption from Self-nanoemulsifying Drug Delivery System (SNEDDS). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26486790/),[ng] / [ml],964,151932,DB01218,Halofantrine
,26486790,C max,"In the in vivo studies, the super-SNEDDS concept proved valid in a rat model with a significantly larger C max for the super-SNEDDS (964 ± 167 ng/mL) than for the SNEDDS (506 ± 112 ng/mL).",The Effect of Digestion and Drug Load on Halofantrine Absorption from Self-nanoemulsifying Drug Delivery System (SNEDDS). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26486790/),[ng] / [ml],506,151933,DB01218,Halofantrine
,26486790,bioavailability,"The bioavailability of Hf dosed in super-SNEDDS (32.9 ± 3.6%) and SNEDDS (22.5 ± 6.3%) did not change significantly with co-administration of orlistat (45.5 ± 7.3% and 21.9 ± 6.5%, respectively).",The Effect of Digestion and Drug Load on Halofantrine Absorption from Self-nanoemulsifying Drug Delivery System (SNEDDS). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26486790/),%,32.9,151934,DB01218,Halofantrine
,26486790,bioavailability,"The bioavailability of Hf dosed in super-SNEDDS (32.9 ± 3.6%) and SNEDDS (22.5 ± 6.3%) did not change significantly with co-administration of orlistat (45.5 ± 7.3% and 21.9 ± 6.5%, respectively).",The Effect of Digestion and Drug Load on Halofantrine Absorption from Self-nanoemulsifying Drug Delivery System (SNEDDS). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26486790/),%,22.5,151935,DB01218,Halofantrine
,26486790,bioavailability,"The bioavailability of Hf dosed in super-SNEDDS (32.9 ± 3.6%) and SNEDDS (22.5 ± 6.3%) did not change significantly with co-administration of orlistat (45.5 ± 7.3% and 21.9 ± 6.5%, respectively).",The Effect of Digestion and Drug Load on Halofantrine Absorption from Self-nanoemulsifying Drug Delivery System (SNEDDS). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26486790/),%,45.5,151936,DB01218,Halofantrine
,26486790,bioavailability,"The bioavailability of Hf dosed in super-SNEDDS (32.9 ± 3.6%) and SNEDDS (22.5 ± 6.3%) did not change significantly with co-administration of orlistat (45.5 ± 7.3% and 21.9 ± 6.5%, respectively).",The Effect of Digestion and Drug Load on Halofantrine Absorption from Self-nanoemulsifying Drug Delivery System (SNEDDS). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26486790/),%,21.9,151937,DB01218,Halofantrine
,26486790,t max,"However, the pharmacokinetic parameters changed; the t max of the super-SNEDDS (1.3 ± 0.1 h) and SNEDDS (2.8 ± 1.2 h) were significantly lower when dosed with orlistat (6.0 ± 1.3 and 6.3 ± 1.2 h, respectively).",The Effect of Digestion and Drug Load on Halofantrine Absorption from Self-nanoemulsifying Drug Delivery System (SNEDDS). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26486790/),h,1.3,151938,DB01218,Halofantrine
,26486790,t max,"However, the pharmacokinetic parameters changed; the t max of the super-SNEDDS (1.3 ± 0.1 h) and SNEDDS (2.8 ± 1.2 h) were significantly lower when dosed with orlistat (6.0 ± 1.3 and 6.3 ± 1.2 h, respectively).",The Effect of Digestion and Drug Load on Halofantrine Absorption from Self-nanoemulsifying Drug Delivery System (SNEDDS). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26486790/),h,2.8,151939,DB01218,Halofantrine
,26486790,t max,"However, the pharmacokinetic parameters changed; the t max of the super-SNEDDS (1.3 ± 0.1 h) and SNEDDS (2.8 ± 1.2 h) were significantly lower when dosed with orlistat (6.0 ± 1.3 and 6.3 ± 1.2 h, respectively).",The Effect of Digestion and Drug Load on Halofantrine Absorption from Self-nanoemulsifying Drug Delivery System (SNEDDS). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26486790/),h,6.0,151940,DB01218,Halofantrine
,26486790,t max,"However, the pharmacokinetic parameters changed; the t max of the super-SNEDDS (1.3 ± 0.1 h) and SNEDDS (2.8 ± 1.2 h) were significantly lower when dosed with orlistat (6.0 ± 1.3 and 6.3 ± 1.2 h, respectively).",The Effect of Digestion and Drug Load on Halofantrine Absorption from Self-nanoemulsifying Drug Delivery System (SNEDDS). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26486790/),h,6.3,151941,DB01218,Halofantrine
,2049260,Cmax,"Cmax values of halofantrine and desbutylhalofantrine (n = 12) were 1192 +/- 410 (mean +/- s.d.) and 397 +/- 160 ng ml-1 with tmax values of 16 +/- 2 and 55 +/- 26 h, respectively.",Pharmacokinetics of halofantrine in Thai patients with acute uncomplicated falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049260/),[ng] / [ml],1192,152873,DB01218,Halofantrine
,2049260,Cmax,"Cmax values of halofantrine and desbutylhalofantrine (n = 12) were 1192 +/- 410 (mean +/- s.d.) and 397 +/- 160 ng ml-1 with tmax values of 16 +/- 2 and 55 +/- 26 h, respectively.",Pharmacokinetics of halofantrine in Thai patients with acute uncomplicated falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049260/),[ng] / [ml],397,152874,DB01218,Halofantrine
,2049260,tmax,"Cmax values of halofantrine and desbutylhalofantrine (n = 12) were 1192 +/- 410 (mean +/- s.d.) and 397 +/- 160 ng ml-1 with tmax values of 16 +/- 2 and 55 +/- 26 h, respectively.",Pharmacokinetics of halofantrine in Thai patients with acute uncomplicated falciparum malaria. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049260/),h,16,152875,DB01218,Halofantrine
,2049260,tmax,"Cmax values of halofantrine and desbutylhalofantrine (n = 12) were 1192 +/- 410 (mean +/- s.d.) and 397 +/- 160 ng ml-1 with tmax values of 16 +/- 2 and 55 +/- 26 h, respectively.",Pharmacokinetics of halofantrine in Thai patients with acute uncomplicated falciparum malaria. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049260/),h,55,152876,DB01218,Halofantrine
,2049260,AUC,"AUC was 60.6 +/- 23.9 and 48.5 +/- 22.2 mg l-1 h, respectively, for halofantrine and its metabolite.",Pharmacokinetics of halofantrine in Thai patients with acute uncomplicated falciparum malaria. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049260/),[h·mg] / [l],60.6,152877,DB01218,Halofantrine
,2049260,AUC,"AUC was 60.6 +/- 23.9 and 48.5 +/- 22.2 mg l-1 h, respectively, for halofantrine and its metabolite.",Pharmacokinetics of halofantrine in Thai patients with acute uncomplicated falciparum malaria. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049260/),[h·mg] / [l],48.5,152878,DB01218,Halofantrine
,10426558,Ki,"The mefloquine Ki of metoprolol alpha-hydroxylation and O-demethylation were 3.4 and 5.8 microM respectively, whereas those of halofantrine were 0.15 and 0.32 microM respectively.","In vitro effects of racemates, separate enantiomers and major metabolites of mefloquine and halofantrine on metoprolol biotransformation by rat liver microsomes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10426558/),μM,3.4,156476,DB01218,Halofantrine
,10426558,Ki,"The mefloquine Ki of metoprolol alpha-hydroxylation and O-demethylation were 3.4 and 5.8 microM respectively, whereas those of halofantrine were 0.15 and 0.32 microM respectively.","In vitro effects of racemates, separate enantiomers and major metabolites of mefloquine and halofantrine on metoprolol biotransformation by rat liver microsomes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10426558/),μM,5.8,156477,DB01218,Halofantrine
,10426558,Ki,"The mefloquine Ki of metoprolol alpha-hydroxylation and O-demethylation were 3.4 and 5.8 microM respectively, whereas those of halofantrine were 0.15 and 0.32 microM respectively.","In vitro effects of racemates, separate enantiomers and major metabolites of mefloquine and halofantrine on metoprolol biotransformation by rat liver microsomes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10426558/),μM,0.15,156478,DB01218,Halofantrine
,10426558,Ki,"The mefloquine Ki of metoprolol alpha-hydroxylation and O-demethylation were 3.4 and 5.8 microM respectively, whereas those of halofantrine were 0.15 and 0.32 microM respectively.","In vitro effects of racemates, separate enantiomers and major metabolites of mefloquine and halofantrine on metoprolol biotransformation by rat liver microsomes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10426558/),μM,0.32,156479,DB01218,Halofantrine
,15206992,C(max),"(C(max) 0.43 +/- 0.14 vs 1.06 +/- 0.44 microg ml(-1) (95% CI on the difference 0.30, 0.95); AUC 32.0 +/- 13.6 vs 63.7 +/- 20.1 microg ml(-1) h (95% CI 14.2, 49.1); t(1/2,z:) 90.8 +/- 17.9 vs 157.4 +/- 57.4 h (95% CI 21.7, 111.5)).",Effects of tetracycline on the pharmacokinetics of halofantrine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15206992/),[μg] / [ml],0.43,180436,DB01218,Halofantrine
,15206992,C(max),"(C(max) 0.43 +/- 0.14 vs 1.06 +/- 0.44 microg ml(-1) (95% CI on the difference 0.30, 0.95); AUC 32.0 +/- 13.6 vs 63.7 +/- 20.1 microg ml(-1) h (95% CI 14.2, 49.1); t(1/2,z:) 90.8 +/- 17.9 vs 157.4 +/- 57.4 h (95% CI 21.7, 111.5)).",Effects of tetracycline on the pharmacokinetics of halofantrine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15206992/),[μg] / [ml],1.06,180437,DB01218,Halofantrine
,15206992,AUC,"(C(max) 0.43 +/- 0.14 vs 1.06 +/- 0.44 microg ml(-1) (95% CI on the difference 0.30, 0.95); AUC 32.0 +/- 13.6 vs 63.7 +/- 20.1 microg ml(-1) h (95% CI 14.2, 49.1); t(1/2,z:) 90.8 +/- 17.9 vs 157.4 +/- 57.4 h (95% CI 21.7, 111.5)).",Effects of tetracycline on the pharmacokinetics of halofantrine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15206992/),[h·μg] / [ml],32.0,180438,DB01218,Halofantrine
,15206992,AUC,"(C(max) 0.43 +/- 0.14 vs 1.06 +/- 0.44 microg ml(-1) (95% CI on the difference 0.30, 0.95); AUC 32.0 +/- 13.6 vs 63.7 +/- 20.1 microg ml(-1) h (95% CI 14.2, 49.1); t(1/2,z:) 90.8 +/- 17.9 vs 157.4 +/- 57.4 h (95% CI 21.7, 111.5)).",Effects of tetracycline on the pharmacokinetics of halofantrine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15206992/),[h·μg] / [ml],63.7,180439,DB01218,Halofantrine
,15206992,"t(1/2,z","(C(max) 0.43 +/- 0.14 vs 1.06 +/- 0.44 microg ml(-1) (95% CI on the difference 0.30, 0.95); AUC 32.0 +/- 13.6 vs 63.7 +/- 20.1 microg ml(-1) h (95% CI 14.2, 49.1); t(1/2,z:) 90.8 +/- 17.9 vs 157.4 +/- 57.4 h (95% CI 21.7, 111.5)).",Effects of tetracycline on the pharmacokinetics of halofantrine in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15206992/),h,90.8,180440,DB01218,Halofantrine
,15206992,"t(1/2,z","(C(max) 0.43 +/- 0.14 vs 1.06 +/- 0.44 microg ml(-1) (95% CI on the difference 0.30, 0.95); AUC 32.0 +/- 13.6 vs 63.7 +/- 20.1 microg ml(-1) h (95% CI 14.2, 49.1); t(1/2,z:) 90.8 +/- 17.9 vs 157.4 +/- 57.4 h (95% CI 21.7, 111.5)).",Effects of tetracycline on the pharmacokinetics of halofantrine in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15206992/),h,157.4,180441,DB01218,Halofantrine
less,10211870,bioavailability,The bioavailability of the enantiomers after oral administration was less than 27%.,Pharmacokinetics of halofantrine in the rat: stereoselectivity and interspecies comparisons. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10211870/),%,27,186104,DB01218,Halofantrine
,8562616,recovery,"The recovery of (+/-)-halofantrine from human plasma at 25 and 2000 ng ml-1 was 68.2 and 61.4%, respectively.",A liquid chromatographic assay for the stereospecific quantitative analysis of halofantrine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8562616/),%,68.2,200379,DB01218,Halofantrine
,8562616,recovery,"The recovery of (+/-)-halofantrine from human plasma at 25 and 2000 ng ml-1 was 68.2 and 61.4%, respectively.",A liquid chromatographic assay for the stereospecific quantitative analysis of halofantrine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8562616/),%,61.4,200380,DB01218,Halofantrine
,7619670,"AUC(0,24 h)","3. The mean AUC(0,24 h) of HF in prostrate children was half (7.54 compared with 13.10 micrograms ml-1 h) (P = 0.06), and that for HFm one-third (0.84 compared with 2.51 micrograms ml-1 h) (P < 0.05) of the value in children with uncomplicated malaria.",Halofantrine pharmacokinetics in Kenyan children with non-severe and severe malaria. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7619670/),[h·μg] / [ml],7.54,201030,DB01218,Halofantrine
,7619670,"AUC(0,24 h)","3. The mean AUC(0,24 h) of HF in prostrate children was half (7.54 compared with 13.10 micrograms ml-1 h) (P = 0.06), and that for HFm one-third (0.84 compared with 2.51 micrograms ml-1 h) (P < 0.05) of the value in children with uncomplicated malaria.",Halofantrine pharmacokinetics in Kenyan children with non-severe and severe malaria. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7619670/),[h·μg] / [ml],13.10,201031,DB01218,Halofantrine
,7619670,"AUC(0,24 h)","3. The mean AUC(0,24 h) of HF in prostrate children was half (7.54 compared with 13.10 micrograms ml-1 h) (P = 0.06), and that for HFm one-third (0.84 compared with 2.51 micrograms ml-1 h) (P < 0.05) of the value in children with uncomplicated malaria.",Halofantrine pharmacokinetics in Kenyan children with non-severe and severe malaria. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7619670/),[h·μg] / [ml],0.84,201032,DB01218,Halofantrine
,7619670,"AUC(0,24 h)","3. The mean AUC(0,24 h) of HF in prostrate children was half (7.54 compared with 13.10 micrograms ml-1 h) (P = 0.06), and that for HFm one-third (0.84 compared with 2.51 micrograms ml-1 h) (P < 0.05) of the value in children with uncomplicated malaria.",Halofantrine pharmacokinetics in Kenyan children with non-severe and severe malaria. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7619670/),[h·μg] / [ml],2.51,201033,DB01218,Halofantrine
,3543604,t1/2 beta,"In healthy subjects, quinine is rapidly eliminated (t1/2 beta: 6-12 h).","[Pharmacokinetics of antimalarials: quinine and mefloquine, halofantrine, qinghaosu, amino-4-quinolines]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3543604/),h,6-12,215080,DB01218,Halofantrine
,3543604,t1/2 beta,Chloroquine (t1/2 beta: 6-50 days) and mefloquine (t1/2 beta: 6-33 days) have extensive tissue distribution and prolonged activity after a single dose.,"[Pharmacokinetics of antimalarials: quinine and mefloquine, halofantrine, qinghaosu, amino-4-quinolines]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3543604/),d,6-50,215081,DB01218,Halofantrine
,3543604,t1/2 beta,Chloroquine (t1/2 beta: 6-50 days) and mefloquine (t1/2 beta: 6-33 days) have extensive tissue distribution and prolonged activity after a single dose.,"[Pharmacokinetics of antimalarials: quinine and mefloquine, halofantrine, qinghaosu, amino-4-quinolines]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3543604/),d,6-33,215082,DB01218,Halofantrine
,3543604,t1/2 beta,"In healthy subjects, the t1/2 beta of this metabolite is 9 to 18 days in plasma.","[Pharmacokinetics of antimalarials: quinine and mefloquine, halofantrine, qinghaosu, amino-4-quinolines]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3543604/),d,9 to 18,215083,DB01218,Halofantrine
,3543604,elimination half-life,Halofantrine has an elimination half-life of between 1.3 and 6.6 days.,"[Pharmacokinetics of antimalarials: quinine and mefloquine, halofantrine, qinghaosu, amino-4-quinolines]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3543604/),d,1.3 and 6.6,215084,DB01218,Halofantrine
,3543604,elimination half-life,"In rabbits, the elimination half-life in plasma was found to be 40 min.","[Pharmacokinetics of antimalarials: quinine and mefloquine, halofantrine, qinghaosu, amino-4-quinolines]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3543604/),min,40,215085,DB01218,Halofantrine
,25895956,flow rate,"Lumefantrine and 97-63 were separated on a Waters Atlantis C18 (4.6×50 mm, 5.0 μm) column under isocratic condition with mobile phase consisting of acetonitrile: methanol (50:50, v/v) and ammonium formate buffer (10 mM, pH 4.5) in the ratio of 95:5 (v/v) at a flow rate of 0.65 mL/min.",Simultaneous quantification of proposed anti-malarial combination comprising of lumefantrine and CDRI 97-78 in rat plasma using the HPLC-ESI-MS/MS method: application to drug interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25895956/),[ml] / [min],0.65,218559,DB01218,Halofantrine
,25895956,relative bioavailability,"Upon coadministration of 97-78, the relative bioavailability of lumefantrine significantly decreased to 64.41%.",Simultaneous quantification of proposed anti-malarial combination comprising of lumefantrine and CDRI 97-78 in rat plasma using the HPLC-ESI-MS/MS method: application to drug interaction study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25895956/),%,64.41,218560,DB01218,Halofantrine
,11684408,lymphatic transport,"The lymphatic transport for halofantrine was 11.1+/-1.2 after administration of trilinolein, 9.0+/-3.5 for trilinolenin and 8.6+/-2.2 for triolein and the total amount of halofantrine transported in the lymph was linear proportional with the amount of triglyceride in the lymph.",Comparison of total oral bioavailability and the lymphatic transport of halofantrine from three different unsaturated triglycerides in lymph-cannulated conscious rats. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11684408/),,11.1,222090,DB01218,Halofantrine
,11684408,lymphatic transport,"The lymphatic transport for halofantrine was 11.1+/-1.2 after administration of trilinolein, 9.0+/-3.5 for trilinolenin and 8.6+/-2.2 for triolein and the total amount of halofantrine transported in the lymph was linear proportional with the amount of triglyceride in the lymph.",Comparison of total oral bioavailability and the lymphatic transport of halofantrine from three different unsaturated triglycerides in lymph-cannulated conscious rats. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11684408/),,9.0,222091,DB01218,Halofantrine
,11684408,lymphatic transport,"The lymphatic transport for halofantrine was 11.1+/-1.2 after administration of trilinolein, 9.0+/-3.5 for trilinolenin and 8.6+/-2.2 for triolein and the total amount of halofantrine transported in the lymph was linear proportional with the amount of triglyceride in the lymph.",Comparison of total oral bioavailability and the lymphatic transport of halofantrine from three different unsaturated triglycerides in lymph-cannulated conscious rats. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11684408/),,8.6,222092,DB01218,Halofantrine
,20448843,recoveries,The mean recoveries were 88.2% for lumefatrine and 84.5% for the I.S.,A modified method for determination of lumefantrine in human plasma by HPLC-UV and combination of protein precipitation and solid-phase extraction: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20448843/),%,88.2,232530,DB01218,Halofantrine
,20448843,recoveries,The mean recoveries were 88.2% for lumefatrine and 84.5% for the I.S.,A modified method for determination of lumefantrine in human plasma by HPLC-UV and combination of protein precipitation and solid-phase extraction: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20448843/),%,84.5,232531,DB01218,Halofantrine
,1743249,parasite clearance time,All patients responded to treatment with a mean parasite clearance time of 52.7 h and a mean fever clearance time of 33.8 h.,Pharmacokinetics of halofantrine and n-desbutylhalofantrine in patients with falciparum malaria following a multiple dose regimen of halofantrine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1743249/),h,52.7,243010,DB01218,Halofantrine
,1743249,fever clearance time,All patients responded to treatment with a mean parasite clearance time of 52.7 h and a mean fever clearance time of 33.8 h.,Pharmacokinetics of halofantrine and n-desbutylhalofantrine in patients with falciparum malaria following a multiple dose regimen of halofantrine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1743249/),h,33.8,243011,DB01218,Halofantrine
,1743249,maximum plasma concentration (Cmax),"The following kinetic parameters (mean values) were determined for HAL and BHAL, respectively: maximum plasma concentration (Cmax) = 896 and 491 ng.",Pharmacokinetics of halofantrine and n-desbutylhalofantrine in patients with falciparum malaria following a multiple dose regimen of halofantrine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1743249/),ng,896,243012,DB01218,Halofantrine
,1743249,maximum plasma concentration (Cmax),"The following kinetic parameters (mean values) were determined for HAL and BHAL, respectively: maximum plasma concentration (Cmax) = 896 and 491 ng.",Pharmacokinetics of halofantrine and n-desbutylhalofantrine in patients with falciparum malaria following a multiple dose regimen of halofantrine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1743249/),ng,491,243013,DB01218,Halofantrine
,1743249,time to reach the Cmax (tmax),ml-1; time to reach the Cmax (tmax) = 15 and 56 h; elimination half-life (t1/2) = 91 and 79 h and the mean residence time (MRT) = 71 and 102 h.,Pharmacokinetics of halofantrine and n-desbutylhalofantrine in patients with falciparum malaria following a multiple dose regimen of halofantrine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1743249/),h,15,243014,DB01218,Halofantrine
,1743249,time to reach the Cmax (tmax),ml-1; time to reach the Cmax (tmax) = 15 and 56 h; elimination half-life (t1/2) = 91 and 79 h and the mean residence time (MRT) = 71 and 102 h.,Pharmacokinetics of halofantrine and n-desbutylhalofantrine in patients with falciparum malaria following a multiple dose regimen of halofantrine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1743249/),h,56,243015,DB01218,Halofantrine
,1743249,elimination half-life (t1/2),ml-1; time to reach the Cmax (tmax) = 15 and 56 h; elimination half-life (t1/2) = 91 and 79 h and the mean residence time (MRT) = 71 and 102 h.,Pharmacokinetics of halofantrine and n-desbutylhalofantrine in patients with falciparum malaria following a multiple dose regimen of halofantrine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1743249/),h,91,243016,DB01218,Halofantrine
,1743249,elimination half-life (t1/2),ml-1; time to reach the Cmax (tmax) = 15 and 56 h; elimination half-life (t1/2) = 91 and 79 h and the mean residence time (MRT) = 71 and 102 h.,Pharmacokinetics of halofantrine and n-desbutylhalofantrine in patients with falciparum malaria following a multiple dose regimen of halofantrine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1743249/),h,79,243017,DB01218,Halofantrine
,1743249,mean residence time (MRT),ml-1; time to reach the Cmax (tmax) = 15 and 56 h; elimination half-life (t1/2) = 91 and 79 h and the mean residence time (MRT) = 71 and 102 h.,Pharmacokinetics of halofantrine and n-desbutylhalofantrine in patients with falciparum malaria following a multiple dose regimen of halofantrine. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1743249/),h,71,243018,DB01218,Halofantrine
,1743249,mean residence time (MRT),ml-1; time to reach the Cmax (tmax) = 15 and 56 h; elimination half-life (t1/2) = 91 and 79 h and the mean residence time (MRT) = 71 and 102 h.,Pharmacokinetics of halofantrine and n-desbutylhalofantrine in patients with falciparum malaria following a multiple dose regimen of halofantrine. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1743249/),h,102,243019,DB01218,Halofantrine
,25975936,flow rate,"PPQ and 97-63 were separated using acetonitrile:methanol (50:50, v/v) and ammonium formate buffer (10 mM, pH 4.5) in the ratio of 95:5(v/v) as mobile phase under isocratic conditions at a flow rate of 0.65 mL/min on Waters Atlantis C18 (4.6 × 50 mm, 5.0 µm) column.","Development and validation of an LC-MS/MS method for simultaneous determination of piperaquine and 97-63, the active metabolite of CDRI 97-78, in rat plasma and its application in interaction study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25975936/),[ml] / [min],0.65,252398,DB01218,Halofantrine
,25975936,extraction recoveries,"The extraction recoveries of PPQ and 97-63 ranged from 90.58 to 105.48%, while for the internal standard, it was 94.27%.","Development and validation of an LC-MS/MS method for simultaneous determination of piperaquine and 97-63, the active metabolite of CDRI 97-78, in rat plasma and its application in interaction study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25975936/),%,90.58 to 105.48,252399,DB01218,Halofantrine
,25975936,extraction recoveries,"The extraction recoveries of PPQ and 97-63 ranged from 90.58 to 105.48%, while for the internal standard, it was 94.27%.","Development and validation of an LC-MS/MS method for simultaneous determination of piperaquine and 97-63, the active metabolite of CDRI 97-78, in rat plasma and its application in interaction study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25975936/),%,94.27,252400,DB01218,Halofantrine
,25975936,AUC0-∞,The co-administration of CDRI 97-78 caused significant decrease in AUC0-∞ of PPQ from 31.52 ± 2.68 to 14.84 ± 4.33 h*µg/mL.,"Development and validation of an LC-MS/MS method for simultaneous determination of piperaquine and 97-63, the active metabolite of CDRI 97-78, in rat plasma and its application in interaction study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25975936/),[h·μg] / [ml],31.52,252401,DB01218,Halofantrine
,25975936,AUC0-∞,The co-administration of CDRI 97-78 caused significant decrease in AUC0-∞ of PPQ from 31.52 ± 2.68 to 14.84 ± 4.33 h*µg/mL.,"Development and validation of an LC-MS/MS method for simultaneous determination of piperaquine and 97-63, the active metabolite of CDRI 97-78, in rat plasma and its application in interaction study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25975936/),[h·μg] / [ml],14.84,252402,DB01218,Halofantrine
,17952423,C(max),"In the case of halofantrine, C(max) decreased from 179 +/- 119 to 98 +/- 32 ng/ml, and the AUC was reduced from 17,450 +/- 4,611 to 11,821 +/- 4,069 ng x h/ml.",Effect of kolanut on the pharmacokinetics of the antimalarial drug halofantrine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17952423/),[ng] / [ml],179,270783,DB01218,Halofantrine
,17952423,C(max),"In the case of halofantrine, C(max) decreased from 179 +/- 119 to 98 +/- 32 ng/ml, and the AUC was reduced from 17,450 +/- 4,611 to 11,821 +/- 4,069 ng x h/ml.",Effect of kolanut on the pharmacokinetics of the antimalarial drug halofantrine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17952423/),[ng] / [ml],98,270784,DB01218,Halofantrine
,17952423,AUC,"In the case of halofantrine, C(max) decreased from 179 +/- 119 to 98 +/- 32 ng/ml, and the AUC was reduced from 17,450 +/- 4,611 to 11,821 +/- 4,069 ng x h/ml.",Effect of kolanut on the pharmacokinetics of the antimalarial drug halofantrine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17952423/),[h·ng] / [ml],"17,450",270785,DB01218,Halofantrine
,17952423,AUC,"In the case of halofantrine, C(max) decreased from 179 +/- 119 to 98 +/- 32 ng/ml, and the AUC was reduced from 17,450 +/- 4,611 to 11,821 +/- 4,069 ng x h/ml.",Effect of kolanut on the pharmacokinetics of the antimalarial drug halofantrine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17952423/),[h·ng] / [ml],"11,821",270786,DB01218,Halofantrine
,17952423,C(max),"C(max) of desbutylhalofantrine decreased from 124 +/- 41 to 62 +/- 23 ng/ml and the AUC from 13,341 +/- 4,749 to 7,359 +/- 3,018 ng x h/ml when kolanut was co-administered.",Effect of kolanut on the pharmacokinetics of the antimalarial drug halofantrine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17952423/),[ng] / [ml],124,270787,DB01218,Halofantrine
,17952423,C(max),"C(max) of desbutylhalofantrine decreased from 124 +/- 41 to 62 +/- 23 ng/ml and the AUC from 13,341 +/- 4,749 to 7,359 +/- 3,018 ng x h/ml when kolanut was co-administered.",Effect of kolanut on the pharmacokinetics of the antimalarial drug halofantrine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17952423/),[ng] / [ml],62,270788,DB01218,Halofantrine
,17952423,AUC,"C(max) of desbutylhalofantrine decreased from 124 +/- 41 to 62 +/- 23 ng/ml and the AUC from 13,341 +/- 4,749 to 7,359 +/- 3,018 ng x h/ml when kolanut was co-administered.",Effect of kolanut on the pharmacokinetics of the antimalarial drug halofantrine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17952423/),[h·ng] / [ml],"13,341",270789,DB01218,Halofantrine
,17952423,AUC,"C(max) of desbutylhalofantrine decreased from 124 +/- 41 to 62 +/- 23 ng/ml and the AUC from 13,341 +/- 4,749 to 7,359 +/- 3,018 ng x h/ml when kolanut was co-administered.",Effect of kolanut on the pharmacokinetics of the antimalarial drug halofantrine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17952423/),[h·ng] / [ml],"7,359",270790,DB01218,Halofantrine
